Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Profit After Tax (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Profit After Tax data on record, last reported at -$30.9 million in Q3 2025.

  • For Q3 2025, Profit After Tax fell 126.45% year-over-year to -$30.9 million; the TTM value through Sep 2025 reached -$68.2 million, up 3.92%, while the annual FY2024 figure was -$59.6 million, 66.71% up from the prior year.
  • Profit After Tax reached -$30.9 million in Q3 2025 per BTAI's latest filing, down from -$19.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$7.3 million in Q1 2025 and bottomed at -$54.8 million in Q4 2022.
  • Average Profit After Tax over 4 years is -$30.8 million, with a median of -$30.9 million recorded in 2025.
  • Peak YoY movement for Profit After Tax: skyrocketed 84.49% in 2024, then tumbled 131.2% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$54.8 million in 2022, then soared by 59.39% to -$22.3 million in 2023, then surged by 51.21% to -$10.9 million in 2024, then tumbled by 184.66% to -$30.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$30.9 million in Q3 2025, -$19.2 million in Q2 2025, and -$7.3 million in Q1 2025.